A therapeutic method for harnessing the body’s immune system to protect against brain damage is published today by researchers from the Babraham Institute’s Immunology research programme. The collaboration between Prof. Adrian Liston (Babraham Institute) and Prof. Matthew Holt (VIB and KU Leuven; i3S-University of Porto) has produced a targeted delivery system for boosting the numbers of specialised anti-inflammatory immune cells specifically within the brain to restrict brain inflammation and damage. Their brain-specific delivery system protected against brain cell death following brain injury, stroke and in a model of multiple sclerosis. The research is published today in the journal Nature Immunology.
Traumatic brain injury, like that caused during a car accident or a fall, is a significant cause of death worldwide and can cause long-lasting cognitive impairment and dementia in people who survive. A leading cause of this cognitive impairment is the inflammatory response to the injury, with swelling of the brain causing permanent damage. While inflammation in other parts of the body can be addressed therapeutically, but in the brain it problematic due to the presence of the blood-brain barrier, which prevents common anti-inflammatory molecules from getting to the site of trauma.
Prof. Adrian Liston
Prof. Liston, a senior group leader in the Institute’s Immunology programme, explained their approach: “Our bodies have their own anti-inflammatory response, regulatory T cells, which have the ability to sense inflammation and produce a cocktail of natural anti-inflammatories. Unfortunately there are very few of these regulatory T cells in the brain, so they are overwhelmed by the inflammation following an injury. We sought to design a new therapeutic to boost the population of regulatory T cells in the brain, so that they could manage inflammation and reduce the damage caused by traumatic injury.”
The research team found that regulatory T cell numbers were low in the brain because of a limited supply of the crucial survival molecule interleukin 2, also known as IL2. Levels of IL2 are low in the brain compared to the rest of the body as it can’t pass the blood-brain barrier.
Together the team devised a new therapeutic approach that allows more IL2 to be made by brain cells, thereby creating the conditions needed by regulatory T cells to survive. A ‘gene delivery’ system based on an engineered adeno-associated viral vector (AAV) was used: this system can actually cross an intact blood brain barrier and deliver the DNA needed for the brain to produce more IL2 production.
Commenting on the work, Prof. Holt said: “For years, the blood-brain barrier has seemed like an insurmountable hurdle to the efficient delivery of biologics to the brain. Our work, using the latest in viral vector technology, proves that this is no longer the case; in fact, it is possible that under certain circumstances, the blood-brain barrier may actually prove to be therapeutically beneficial, serving to prevent ‘leak’ of therapeutics into the rest of the body.”
Immunofluorescence staining images
These immunofluorescence staining images show how the treatment has reduced the amount of damage after traumatic brain injury when mice were pre-treated with the IL2 treatment. The top layer of brain tissue is visibly thicker in the bottom right image compared to top right. Each row shows the uninjured brain hemisphere (left) and the injured hemisphere (right). The top row shows an untreated brain while the bottom row shows a treated brain, with less damage occurring in the injured hemisphere.
The new therapeutic designed by the research teams was able to boost the levels of the survival molecule IL2 in the brain, up to the same levels found in the blood. This allowed the number of regulatory T cells to build up in the brain, up to 10-fold higher than normal. To test the efficacy of the treatment in a mouse model that closely resembles traumatic brain injury accidents, mice were given carefully controlled brain impacts and then treated with the IL-2 gene delivery system. The scientists found that the treatment was effective at reducing the amount of brain damage following the injury, assessed by comparing both the loss of brain tissue and the ability of the mice to perform in cognitive tests.
Dr Lidia Yshii
Lead author, Dr Lidia Yshii, Assistant Professor at KU Leuven, explained: “Seeing the brains of the mice after the first experiment was a ‘eureka moment’ – we could immediately see that the treatment reduced the size of the injury lesion.”
Recognising the wider potential of a drug capable of controlling brain inflammation, the researchers also tested the effectiveness of the approach in experimental mouse models of multiple sclerosis and stroke. In the model of multiple sclerosis, treating mice during the early symptoms prevented severe paralysis and allowed the mice to recover faster. In a model of stroke, mice treated with the IL2 gene delivery system after a primary stroke were partially protected from secondary strokes occurring two weeks later. In a follow-up study, still undergoing peer review, the research team also demonstrated that the treatment was effective at preventing cognitive decline in ageing mice.
“By understanding and manipulating the immune response in the brain, we were able to develop a gene delivery system for IL2 as a potential treatment for neuroinflammation. With tens of millions of people affected every year, and few treatment options, this has real potential to help people in need. We hope that this system will soon enter clinical trials, essential to test whether the treatment also works in patients." said Prof. Liston.
Dr Ed Needham, a neurocritical care Consultant at Addenbrooke’s Hospital who was not a part of the study, commented on the clinical relevance of these results: “There is an urgent clinical need to develop treatments which can prevent secondary injury that occurs after a traumatic brain injury. Importantly these treatments have to be safe for use in critically unwell patients who are at high risk of life-threatening infections. Current anti-inflammatory drugs act on the whole immune system, and may therefore increase patients' susceptibility to such infections. The exciting progress in this study is that, not only can the treatment successfully reduce the brain damage caused by inflammation, but it can do so without affecting the rest of the body's immune system, thereby preserving the natural defences needed to survive critical illness."
Yshii, L, Pasciuto, E, Bielefeld, P, et al. Astrocyte-targeted gene delivery of interleukin 2 specifically increases brain-resident regulatory T cell numbers and protects against pathological neuroinflammation
Honor Pollard, Communications Officer, email@example.com, 01223 486093
Header image description:
Left: The top image shows an untreated mouse brain after a controlled impact, the site of damage can be seen by the dark circular impact site. The bottom brain is from a treated mouse 14 days after the impact, the absence of a visible impact site shows the success of the treatment in preventing brain tissue loss.
Middle: These immunofluorescence staining images show how the treatment has reduced the amount of damage after traumatic brain injury when mice were pre-treated with the IL2 treatment. The top layer of brain tissue is visibly thicker in the bottom right image compared to top right. Each row shows the uninjured brain hemisphere (left) and the injured hemisphere (right). The top row shows an untreated brain while the bottom row shows a treated brain, with less damage occurring in the injured hemisphere.
Right: A magnetic resonance imaging (MRI) scan of the brains of two mice after a controlled impact to create a traumatic brain injury. The arrow shows there the impact was made, the grey area below the arrow shows the size of the lesion. The amount of brain swelling is visibly reduced in the brain of the treated mouse (bottom).
Affiliated authors (in author order):Pascal Bielefeld, postdoctoral researcher, Liston labJames Dooley, senior staff scientist, Liston lab
Lubna Kouser, postdoctoral researcher, Liston labOliver Burton, senior scientist, Liston labSamar Tareen, visiting scientist, Liston lab
Carlos Roca, former senior scientist, Liston lab
Kailash Singh, visiting fellow, Liston lab
Carly Whyte, former postdoctoral researcher, Liston labAmy Dashwood, PhD student, Liston labMeryem Aloulou, visiting fellow, Liston lab
Adrian Liston, Immunology programme group leader
This research was funded primarily by the European Research Council (ERC), with additional funding from the Research Foundation – Flanders (FWO) and the Biotechnology and Biological Sciences Research Council (BBSRC) and the Vlaams Instituut voor Biotechnologie (VIB).
Animal research statement
As a publicly funded research institute, the Babraham Institute is committed to engagement and transparency in all aspects of its research. Animal research included in this study was conducted across a number of Institutes. All animal procedures in this study were approved by the KU Leuven Animal Ethics Committee, the University of Amsterdam, or the Babraham Institute Animal Welfare and Ethics Review Body taking into account relevant national and European guidelines. This research involved models of inflammatory brain conditions including Traumatic Brain Injury (TBI), Multiple Sclerosis (MS) and stroke. Cognitive tests were used to measure the extent to which the treatment worked as well as dissection and imaging of mouse brains. To study the mechanism of increased T cell populations, the circulatory systems of two mice were connected (parabiosis).
Experiments were performed in accordance with the local overseeing authority. Animal husbandry and experimentation complied with existing European Union and national legislation and local standards.
Please follow the link for further details of the Babraham Institute’s animal research and our animal welfare practices. http://www.babraham.ac.uk/about-us/animal-research
Find out more about the Liston lab
News 23 July 2021
News 22 July 2020
The Babraham Institute undertakes world-class life sciences research to generate new knowledge of biological mechanisms underpinning ageing, development and the maintenance of health. Our research focuses on cellular signalling, gene regulation and the impact of epigenetic regulation at different stages of life. By determining how the body reacts to dietary and environmental stimuli and manages microbial and viral interactions, we aim to improve wellbeing and support healthier ageing. The Institute is strategically funded by the Biotechnology and Biological Sciences Research Council (BBSRC), part of UK Research and Innovation, through Institute Strategic Programme Grants and an Institute Core Capability Grant and also receives funding from other UK research councils, charitable foundations, the EU and medical charities.
The Biotechnology and Biological Sciences Research Council (BBSRC) is part of UK Research and Innovation, a non-departmental public body funded by a grant-in-aid from the UK government.
BBSRC invests in world-class bioscience research and training on behalf of the UK public. Our aim is to further scientific knowledge, to promote economic growth, wealth and job creation and to improve quality of life in the UK and beyond.
Funded by government, BBSRC invested £451 million in world-class bioscience in 2019-20. We support research and training in universities and strategically funded institutes. BBSRC research and the people we fund are helping society to meet major challenges, including food security, green energy and healthier, longer lives. Our investments underpin important UK economic sectors, such as farming, food, industrial biotechnology and pharmaceuticals.
KU Leuven is a leading European university dedicated to research, education and service to society. It is a founding member of the League of European Research Universities (LERU) and has a strong European and international orientation. Its sizeable academic staff conducts basic and applied research in a comprehensive range of disciplines. University Hospitals Leuven, its network of research hospitals, provides high-quality healthcare and develops new therapeutic and diagnostic insights with an emphasis on translational research. The University welcomes more 50,000 students from over 140 countries. Its doctoral schools organise internationally oriented PhD programmes for over 4,500 doctoral students. More info: www.kuleuven.be/english
VIB is an excellence-based entrepreneurial research institute in life sciences located in Flanders, Belgium. VIB’s basic research leads to new and innovative insights into normal and pathological life processes. It unites the expertise of all its collaborators and research groups in a single institute, firmly based on its close partnership with 5 Flemish universities (Ghent University, KU Leuven, University of Antwerp, Vrije Universiteit Brussel, and Hasselt University) and supported by a solid funding program from the Flemish government. VIB has an excellent track record of translating basic scientific results into pharmaceutical, agricultural and industrial applications. Since its foundation in 1996, VIB has created 30 start-up companies, now employing over 900 people. More information: www.vib.be.
26 May 2022